Equities

Tsubota Laboratory Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4890:TYO

Tsubota Laboratory Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)264.00
  • Today's Change-2.00 / -0.75%
  • Shares traded152.30k
  • 1 Year change-37.74%
  • Beta1.2120
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

  • Revenue in JPY (TTM)710.56m
  • Net income in JPY-398.77m
  • Incorporated2012
  • Employees17.00
  • Location
    Tsubota Laboratory Inc8FAoyama KK Bldg., 2-26-35, Minami-AoyamaSHINJUKU-KU 160-8582JapanJPN
  • Phone+81 363842866
  • Websitehttps://tsubota-lab.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ribomic Inc750.00k-1.04bn4.46bn25.00--1.38--5,940.37-22.23-22.230.015959.350.0002--0.017330,000.00-31.47-29.95-32.94-31.15-----138,954.00-2,725.9520.66--0.00-----55.550.5173---6.86--
Human Metabolome Technologies Inc1.43bn207.06m4.48bn62.0021.342.3514.023.1335.4235.42248.83321.250.623710.294.9123,060,290.009.0310.5410.9813.5960.4866.6514.4817.245.13391.350.055520.988.125.405.42--33.68--
Modalis Therapeutics Corp0.00-2.15bn5.16bn14.00--1.83-----28.13-28.130.0032.230.00-------64.69-47.62-67.23-49.48-------22,365.60-------------63.34---68.51--
D.Western Therapeutics Institute Inc387.62m-632.09m5.48bn21.00--3.82--14.14-13.31-13.318.0926.460.20190.41153.53---32.93-28.15-36.09-30.6889.9792.09-163.07-155.999.48--0.2966---17.801.7451.01---11.74--
TMS Co Ltd0.00-670.20m6.23bn18.00--2.08-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Carna Biosciences, Inc.579.06m-2.17bn6.43bn63.00--20.80--11.11-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
Noile-Immune Biotech Inc7.14m-782.47m6.67bn25.00--1.62--933.57-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
Cyfuse Biomedical KK-100.00bn-100.00bn6.75bn21.00--2.36----------286.90-----------13.87---16.49--68.61---178.864.44--0.3224--324.2710.9412.43--182.58--
Tsubota Laboratory Inc710.56m-398.77m6.86bn17.00--6.21--9.66-15.53-15.5327.5542.860.35940.452250.4641,797,700.00-20.170.1041-29.560.151781.6571.43-56.120.22162.60--0.06340.00101.4925.17132.08132.7026.42--
Chiome Bioscience Inc593.29m-982.78m7.64bn47.00--6.71--12.88-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Linical Co Ltd9.32bn-1.77bn7.74bn598.00--1.25--0.8309-78.51-78.51412.61251.020.5937--3.6215,584,280.00-11.302.59-20.504.1917.4829.24-19.033.74---192.930.293377.26-15.20-0.9283-259.37---42.014.24
OncoTherapy Science, Inc.784.25m-881.65m7.91bn47.00--3.70--10.09-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
PRISM BioLab Co Ltd677.33m-833.70m7.98bn35.00--2.94--11.78-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
Medinet Co Ltd787.09m-1.36bn8.27bn107.00--2.39--10.50-5.12-5.122.9712.950.170111.083.007,355,991.00-29.29-22.42-31.04-23.6413.5817.68-172.25-173.5911.33--0.00--5.440.6867-6.67--10.06--
Chordia Therapeutics Inc0.00-1.46bn8.68bn20.00--3.64-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn8.70bn24.00--4.82--7,834.82-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Data as of Feb 17 2026. Currency figures normalised to Tsubota Laboratory Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.09%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 05 Feb 202617.10k0.07%
Asset Management One Co., Ltd.as of 17 Feb 20256.30k0.02%
Mitsubishi UFJ Asset Management Co., Ltd.as of 26 Feb 20240.000.00%
Data from 31 Dec 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.